PAS 2090 LIFE CYCLE ASSESSMENT

PAS 2090 is a pharmaceutical sustainability standard that provides product category rules for conducting environmental Life Cycle Assessments of medicines. Developed by the British Standards Institute (BSI), the standard establishes a consistent methodology for evaluating the environmental impact of medicines across their full life cycle.

Tunley Environmental's service applies the PAS 2090 framework to carry out a comprehensive Life Cycle Assessment for pharmaceutical products. This means measuring and reporting the full environmental impacts of a medicine across its entire life cycle.

REQUEST PAS 2090 QUOTE

WHY IS PAS 2090 IMPORTANT FOR PHARMACEUTICAL SECTORS?

Pharmaceutical companies are under increasing pressure to understand and reduce the environmental impact of medicines. Our PAS 2090 Life Cycle Assessment service provides a structured and standardised approach to measuring the full environmental footprint of pharmaceutical products.

Using the first global pharmaceutical sustainability standard, we conduct a comprehensive LCA for pharma products to quantify the pharmaceutical carbon footprint, along with water, nature and health impacts. Identifying opportunities for improvements across the products life cycle, from raw material extraction, through to end-of-life disposal.

This assessment helps pharmaceutical organisations produce credible sustainability data, meet procurement requirements and prepare for future environmental regulations.

Conducting an LCA for pharma products aligned with PAS 2090 allows pharmaceutical companies to:

Measure the environmental impact of medicines using a recognised methodology
Identify environmental hotspots in product supply chains
Understand the carbon footprint of pharmaceutical products and produce reduction strategies
Produce credible, verified environmental disclosures
Support sustainability reporting and ESG commitments
Prepare for emerging environmental regulations.

By quantifying the pharmaceutical environmental footprint, organisations gain the insights needed to identify impact hotspots and develop targeted reduction strategies.

WHAT OUR PAS 2090 LIFE CYCLE ASSESSMENT SERVICE PROVIDES

The pharmaceutical sector is facing growing pressure from healthcare systems, investors, and regulators to improve sustainability transparency. Our PAS 2090 service delivers a complete and verifiable Life Cycle Assessment for PAS 2090 pharmaceutical products.

The assessment measures the full environmental impact of medicines, including greenhouse gas emissions and other environmental indicators. This LCA for pharma products provides organisations with credible data to support long-term sustainability strategies.

The final deliverable is a comprehensive LCA report that includes:

Quantification of the pharmaceutical carbon footprint
Identification of environmental hotspots across the product life cycle
Transparent documentation of data sources and assumptions
A third-party verified baseline report suitable for sustainability disclosure, procurement tenders, and reduction planning

This LCA for pharma products provides organisations with credible data to support long-term sustainability strategies.

The project ran seamlessly from carrying out regular communication between key project stakeholders to the speed of the project execution and completion. We would highly recommend Tunley Environmental to companies looking to complete product LCAs.

Keely Warren

Brand & Communications Manager | Tremco

We used Tunley Environmental to help us with out carbon reduction targets, they conducted an embedded carbon report for one of our key ranges and we are now exploring next steps. I would highly recommend them professional, helpful a great company to work with.

Kieron King

Quality Manager | Inpress

They did exactly what was asked and where we had less than perfect understanding of the issues involved their expertise showed through. The response time to follow up enquiries was excellent and I would happily use Tunley again.

Michelle Smith

Intellectual Property Controller | Power Roll

From start to finish the whole team have excelled in communication and support. They made the entire process seemless, and nothing was too much for them. This is my first full experience completing a carbon assessment, and I couldn't have asked for a better company to complete this with.

Rebecca Druce

SQE Manager | Spacecare

We found all of the Tunley Environmental representatives to be extremely friendly, helpful and knowledgeable. They provided a high standard of service with plenty of advice and support, including regular meetings to update on progress and present findings. We look forward to working with Tunley Environmental again on future projects.

Mary Bellamy

Lead Research Nurse | University Hospitals Birmingham NHS Foundation Trust

OUR PAS 2090 LIFE CYCLE ASSESSMENT METHODOLOGY

Our methodology follows internationally recognised Life Cycle Assessment principles while applying the PAS 2090 pharmaceutical products framework.

As a science-based environmental sustainability consultancy, Tunley ensures every assessment is conducted with scientific rigour and transparency. Our PhD-level scientists combine advanced environmental modelling with industry knowledge to produce robust and defensible results.

Our assessment are conducted according to PAS 2090:2025 - Pharmaceutical products - Product Category Rules for environmental Life Cycle Assessments. The framework builds upon established Life Cycle Assessment standards including ISO 14040 and ISO 14044.

Goal and Scope Definition

Define the functional unit, boundaries and objectives of the LCA for pharma products.

Life Cycle Inventory

Collect detailed supply chain and manufacturing data covering all life cycle stages.

Impact Assessment

Quantify greenhouse gas emissions and calculate the pharmaceutical carbon footprint.

Interpretation

Identifying environmental hotspots contributing to the environmental impact of medicines.

Reporting

Produce a transparent report aligned with PAS 2090 product category rules.

WHY CHOOSE TUNLEY?

Tunley Environmental is a science-based environmental sustainability consultancy specialising in Life Cycle Assessment and environmental footprint analysis.

EXPERTISE

Our team of sustainability professionals and PhD-Level Scientists combine scientific rigor with real-world experience in environmental consulting.

TAILORED APPROACH

We provide industry-specific solutions for business of all sizes and sectors.

PROVEN IMPACT

Tunley Environmental has a track record of delivering measurable sustainability results for diverse clients.

Want To Know More?

FREQUENTLY ASKED QUESTIONS

What is PAS 2090 for Pharmaceutical products?

PAS 2090 is a pharmaceutical sustainability standard that provides product category rules for conducting environmental life cycle assessments of medicines. It enables organisations to measure the environmental impact of medicines across the full product life cycle using consistent and transparent methodology.

How does PAS 2090 measure the environmental impact of medicines?

PAS 2090 pharmaceutical product assessments use a life cycle assessment approach to evaluate environmental impacts from raw material extraction through to manufacturing, distribution, use and end-of-life. this LCA for pharma products quantifies greenhouse gas emissions and calculates the pharmaceutical carbon footprint of a medicine.

Why are pharmaceutical companies adopting PAS 2090?

Pharmaceutical companies are adopting PAS 2090 to improve transparency around the environmental impact of medicines and to support sustainability reporting. The pharmaceutical sustainability standard also helps organisations to increasing expectations from healthcare systems, investors and regulators.

What data is required for a PAS 2090 Life Cycle Assessment?

A PAS 2090 pharmaceutical products assessment typically requires data across the entire product life cycle, including raw materials, active pharmaceutical ingredients, manufacturing processes, packaging, distribution and disposal. This data is used to calculate the pharmaceutical carbon footprint and other environmental impact indicators.

What is the output of an LCA for pharma products under PAS 2090?

The primary output of a PAS 2090 assessment is a detailed Life Cycle Assessment report. This report quantifies the pharmaceutical carbon footprint, identifies environmental hotspots and provides a transparent overview of the environmental impact of medicines across the product life cycle.

How can PAS 2090 support pharmaceutical sustainability strategies?

By conducting an LCA for pharma products, organisations gain insight into where environmental impacts occur in their supply chains. This allows companies to prioritise reductions in the pharmaceutical carbon footprint, improve product design and reduce the overall environmental impact of medicines.